Agilent Technologies Inc. logo

Agilent Technologies Inc. (A)

Market Closed
3 Jun, 20:00
NYSE NYSE
$
137. 40
+2.35
+1.7401%
Pre Market
$
139. 35
+1.95 +1.4192%
38.16B Market Cap
- P/E Ratio
1.02% Div Yield
2.42M Volume
- Eps
$ 135.05
Previous Close
Add Transaction
Day Range
133.65 138.97
Year Range
108.35 160.27
Want to track A and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
These Analysts Boost Their Forecasts On Agilent After Strong Earnings

These Analysts Boost Their Forecasts On Agilent After Strong Earnings

Agilent Technologies, Inc. A posted better-than-expected third-quarter earnings and issued upbeat fourth-quarter guidance on Wednesday.

Benzinga | 1 year ago
A Stock Earnings: Agilent Technologies Beats EPS, Beats Revenue for Q3 2024

A Stock Earnings: Agilent Technologies Beats EPS, Beats Revenue for Q3 2024

Agilent Technologies (NYSE: A ) just reported results for the third quarter of 2024. Agilent Technologies reported earnings per share of $1.32.

Investorplace | 1 year ago
Agilent Technologies, Inc. (A) Q3 2024 Earnings Call Transcript

Agilent Technologies, Inc. (A) Q3 2024 Earnings Call Transcript

Agilent Technologies, Inc. (NYSE:A ) Q3 2024 Earnings Conference Call August 21, 2024 4:30 PM ET Company Participants Conference Call Participants Operator Ladies and gentlemen, welcome to the Agilent Technologies Q3 2024 Earnings Call. My name is Regina and I will be coordinating your call today.

Seekingalpha | 1 year ago
Agilent (A) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Agilent (A) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for Agilent (A) give a sense of how the business performed in the quarter ended July 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks | 1 year ago
Agilent Technologies (A) Q3 Earnings and Revenues Beat Estimates

Agilent Technologies (A) Q3 Earnings and Revenues Beat Estimates

Agilent Technologies (A) came out with quarterly earnings of $1.32 per share, beating the Zacks Consensus Estimate of $1.25 per share. This compares to earnings of $1.43 per share a year ago.

Zacks | 1 year ago
Agilent beats quarterly results on strong demand from biotech clients

Agilent beats quarterly results on strong demand from biotech clients

Agilent Technologies on Wednesday beat Wall Street estimates for third-quarter profit and revenue, banking on strong demand for its medical tools and equipment used in clinical studies.

Reuters | 1 year ago
Agilent (A) Boosts LSAG Segment With J&W 5Q GC/MS Columns

Agilent (A) Boosts LSAG Segment With J&W 5Q GC/MS Columns

Agilent Technologies (A) launches J&W 5Q GC/MS Columns to address the growing demand for modern laboratories.

Zacks | 1 year ago
Wall Street's Insights Into Key Metrics Ahead of Agilent (A) Q3 Earnings

Wall Street's Insights Into Key Metrics Ahead of Agilent (A) Q3 Earnings

Beyond analysts' top -and-bottom-line estimates for Agilent (A), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended July 2024.

Zacks | 1 year ago
Analysts Estimate Agilent Technologies (A) to Report a Decline in Earnings: What to Look Out for

Analysts Estimate Agilent Technologies (A) to Report a Decline in Earnings: What to Look Out for

Agilent (A) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks | 1 year ago
Agilent (A) Boosts DCG Segment With New ProteoAnalyzer System

Agilent (A) Boosts DCG Segment With New ProteoAnalyzer System

Agilent (A) unveils its new ProteoAnalyzer system in a bid to strengthen its Diagnostics and Genomics Group segment.

Zacks | 1 year ago
Agilent to buy contract drug manufacturer Biovectra for $925 million

Agilent to buy contract drug manufacturer Biovectra for $925 million

Agilent Technologies said on Monday it will acquire contract drug manufacturer Biovectra for $925 million to expand its portfolio of services offered to biotech companies and medical researchers.

Reuters | 1 year ago
History Says These Could Be 3 of the Best Healthcare Stocks to Own in the Second Half of 2024

History Says These Could Be 3 of the Best Healthcare Stocks to Own in the Second Half of 2024

Intuitive Surgical's game-changing robotic surgical systems should continue fueling considerable growth for the business. UnitedHealth is in an excellent position to benefit from the health insurance industry's long-term growth.

Fool | 1 year ago
Loading...
Load More